Yang Shiyu, Xu Liping, Zhuang Haihui, Li Fenglin, Lu Ying
Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Institute of Hematology, Ningbo University, Ningbo, China.
Front Immunol. 2024 May 28;15:1374390. doi: 10.3389/fimmu.2024.1374390. eCollection 2024.
Immunotherapy for hematological malignancies is a rapidly advancing field that has gained momentum in recent years, primarily encompassing chimeric antigen receptor T-cell (CAR-T) therapies, immune checkpoint inhibitors, and other modalities. However, its clinical efficacy remains limited, and drug resistance poses a significant challenge. Therefore, novel immunotherapeutic targets and agents need to be identified. Recently, N6-methyladenosine (m6A), the most prevalent RNA epitope modification, has emerged as a pivotal factor in various malignancies. Reportedly, m6A mutations influence the immunological microenvironment of hematological malignancies, leading to immune evasion and compromising the anti-tumor immune response in hematological malignancies. In this review, we comprehensively summarize the roles of the currently identified m6A modifications in various hematological malignancies, with a particular focus on their impact on the immune microenvironment. Additionally, we provide an overview of the research progress made in developing m6A-targeted drugs for hematological tumor therapy, to offer novel clinical insights.
血液系统恶性肿瘤的免疫治疗是一个近年来发展迅速的领域，近年来势头强劲，主要包括嵌合抗原受体T细胞（CAR-T）疗法、免疫检查点抑制剂及其他治疗方式。然而，其临床疗效仍然有限，耐药性构成了重大挑战。因此，需要确定新的免疫治疗靶点和药物。最近，N6-甲基腺苷（m6A）作为最普遍的RNA表位修饰，已成为各种恶性肿瘤中的关键因素。据报道，m6A突变影响血液系统恶性肿瘤的免疫微环境，导致免疫逃逸并损害血液系统恶性肿瘤中的抗肿瘤免疫反应。在本综述中，我们全面总结了目前已确定的m6A修饰在各种血液系统恶性肿瘤中的作用，特别关注它们对免疫微环境的影响。此外,我们概述了开发用于血液肿瘤治疗的m6A靶向药物的研究进展，以提供新的临床见解。
